209. Will Trump's pharmaceutical tariffs lower prices and secure supply chains?

Episode Summary

Executive Summary: The episode examines Trump’s new pharmaceutical tariffs and U.S.-U.K. pricing deal, arguing they attempt to solve two distinct problems—high U.S. prices for patented drugs and fragile supply chains for generics—through trade tools that may not directly address either. The guest says the U.S. needs better negotiation and targeted industrial policy instead.

Main Topics: Two separate U.S. pharmaceutical problems (Priority: 5/5): The discussion distinguishes between cheap generic drugs that are prone to shortages and branded biologics/patented drugs that drive most spending and are far more expensive in the U.S. Why U.S. drug prices are so high (Priority: 5/5): Boyke explains that the U.S. lacks a universal purchaser and centralized bargaining system, unlike the U.K. or Australia, which allows payers to negotiate lower prices. Trump administration’s trade-based approach (Priority: 5/5): The administration is using Section 232, tariff threats, and country/company deals to try to influence drug pricing and manufacturing, a major departure from standard trade policy. U.S.-U.K. pharmaceutical arrangement (Priority: 4/5): The U.K. agreed to raise its cost-effectiveness threshold in exchange for preferential tariff treatment and exemptions for U.S. pharmaceutical exports. Limits of reshoring and MFN-style pricing (Priority: 4/5): The guest argues that moving manufacturing to the U.S. does not by itself lower prices, and reference pricing is hard to enforce and may not reflect actual discounts. What would actually help supply-chain security (Priority: 5/5): Boyke recommends long-term federal purchase commitments, allied coordination, and incentives for API/key starting material production, especially for generics. Targeted tariffs on inputs, not finished drugs (Priority: 4/5): If tariffs are used, the guest suggests focusing on key starting materials and APIs tied to dependence on China and India rather than broad pharmaceutical tariffs.

Key Arguments: The U.S. pharmaceutical market is really two markets: generics, where the main issue is shortages and supply-chain fragility, and branded drugs, where the main issue is high prices. Generics are cheap in the U.S. but vulnerable because low margins and foreign sourcing make production fragile, especially for sterile injectables and hospital drugs. Branded drugs and biologics account for most spending, and the U.S. pays far above peer countries because pricing is driven by what payers will pay, not manufacturing cost. The Trump administration’s main novelty is using trade policy—tariffs, Section 232, and bilateral deals—to address drug pricing and supply-chain security. The U.S.-U.K. deal may raise U.K. spending on drugs, but it is unclear that this will lower U.S. prices because U.S. pricing depends on domestic bargaining power. Pharmaceutical companies’ announced U.S. manufacturing investments, while large on paper, do not yet show clear evidence of actual reshoring activity. Reshoring manufacturing does not solve pricing if the products remain patented and the U.S. still fails to negotiate lower prices. To secure generic supply chains, the U.S. should use long-term procurement commitments and allied industrial coordination for APIs and key starting materials. Targeted tariffs on inputs from China and India could make sense as a national-security tool, but broad tariffs on finished branded drugs are a poor fit for the real vulnerability.

Data Points: U.S. share of global population: about 4% - Used to contrast U.S. population size with its outsized role in the drug market U.S. share of global pharmaceutical market: 40% - Shows how large U.S. demand is relative to population U.S. population: roughly 340 million - Compared with 8.1 billion worldwide Global population: 8.1 billion - Reference point for U.S. market share comparison Generic/biosimilar share of prescriptions: 9 out of 10 - Generics and biosimilars dominate U.S. prescriptions Generic/biosimilar share of market by volume: 90% - These drugs make up most units dispensed Generic/biosimilar share of spending: 13% - Despite dominating volume, they account for a small share of total spend Unbranded generic price vs OECD: two-thirds of the price - U.S. unbranded generics are cheaper than in other OECD countries Branded drugs/biosimilars share by volume: roughly 10% - Small share of prescriptions but high cost Branded drugs/biosimilars share of spending: 87% - These drugs drive most U.S. pharmaceutical spending Branded drugs/biosimilars price vs OECD: 278% of the OECD average - RAND 2024 comparison cited in the episode Insulin price comparison: 9 times higher - U.S. insulin drugs versus 33 OECD countries U.K. threshold increase: 25% - The U.K. agreed to raise its cost-effectiveness threshold for listing medicines in the NHS Preferential tariff period: 3 years - U.S.-U.K. pharmaceutical tariff arrangement duration U.K. medical technology tariff rate: 10% - Tariff rate maintained on U.K. medical technology exports Pharmaceutical company U.S. manufacturing announcements: as much as $480 billion - Announced investment commitments tied to administration deals Expected U.K. bill increase by 2029: around £1 billion per year - Estimated impact of the pricing threshold shift according to press releases Bookend timeframe for some company deals: 2029 - Many company arrangements are described as limited through 2029

Pivotal Quotes: "The U.S. represents about 4% of the global population ... but we represent 40% of the world's global pharmaceutical market." — Tom Boyke: Explaining why U.S. policy has outsized global effects "The big distinguishing factor is the use of trade arrangements." — Tom Boyke: Describing how the Trump administration differs from previous administrations "Whether they're making a pill in Ireland or the U.K. or Michigan doesn't really matter. It's how the United States chooses to negotiate with the companies over prices." — Tom Boyke: Arguing that reshoring alone will not fix U.S. drug prices

Implications: Listeners should expect more tariff-driven drug policy, but the episode suggests the current approach is unlikely to materially cut U.S. prices or solve generic shortages. Real progress would require stronger domestic negotiation, targeted input-focused policy, and allied supply-chain coordination.